vTv Therapeutics Inc (VTVT)
24.85
+0.42
(+1.70%)
USD |
NASDAQ |
Apr 23, 11:46
vTv Therapeutics Total Liabilities (Quarterly): 29.57M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 29.57M |
September 30, 2023 | 29.44M |
June 30, 2023 | 28.83M |
March 31, 2023 | 28.42M |
December 31, 2022 | 27.40M |
September 30, 2022 | 27.88M |
June 30, 2022 | 29.60M |
March 31, 2022 | 13.91M |
December 31, 2021 | 10.25M |
September 30, 2021 | 8.369M |
June 30, 2021 | 9.293M |
March 31, 2021 | 10.38M |
December 31, 2020 | 11.00M |
September 30, 2020 | 12.83M |
June 30, 2020 | 16.78M |
March 31, 2020 | 17.01M |
December 31, 2019 | 18.11M |
September 30, 2019 | 19.00M |
June 30, 2019 | 21.91M |
Date | Value |
---|---|
March 31, 2019 | 23.36M |
December 31, 2018 | 28.93M |
September 30, 2018 | 35.16M |
June 30, 2018 | 43.41M |
March 31, 2018 | 43.12M |
December 31, 2017 | 47.52M |
September 30, 2017 | 29.72M |
June 30, 2017 | 30.04M |
March 31, 2017 | 30.14M |
December 31, 2016 | 22.92M |
September 30, 2016 | 10.81M |
June 30, 2016 | 10.05M |
March 31, 2016 | 8.911M |
December 31, 2015 | 7.971M |
September 30, 2015 | 6.129M |
June 30, 2015 | 99.91M |
March 31, 2015 | 85.50M |
December 31, 2014 | 73.67M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
8.369M
Minimum
Sep 2021
29.60M
Maximum
Jun 2022
19.47M
Average
18.11M
Median
Dec 2019
Total Liabilities (Quarterly) Benchmarks
Altimmune Inc | 16.54M |
Palatin Technologies Inc | 24.94M |
Oragenics Inc | 1.798M |
Viking Therapeutics Inc | 20.07M |
G1 Therapeutics Inc | 86.15M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 11.02M |
Shareholders Equity (Quarterly) | -24.68M |